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ALS2 mutations
Juvenile amyotrophic lateral sclerosis and generalized dystonia
ABSTRACT
Objective: To determine the genetic etiology in 2 consanguineous families who presented a novel
phenotype of autosomal recessive juvenile amyotrophic lateral sclerosis associated with gener-
alized dystonia.
Methods: A combination of homozygosity mapping and whole-exome sequencing in the first
family and Sanger sequencing of candidate genes in the second family were used.
Results: Both families were found to have homozygous loss-of-function mutations in the amyotro-
phic lateral sclerosis 2 (juvenile) (ALS2) gene.
Conclusions: We report generalized dystonia and cerebellar signs in association with ALS2-related
disease. We suggest that the ALS2 gene should be screened for mutations in patients who present
with a similar phenotype. Neurology® 2014;82:1065–1067
GLOSSARY
ALS2 5 amyotrophic lateral sclerosis 2 (juvenile); JALS 5 juvenile-onset amyotrophic lateral sclerosis; NHLBI 5 National
Heart, Lung, and Blood Institute.
Mutations in the amyotrophic lateral sclerosis 2 (juvenile) (ALS2) gene (Online Mendelian Inheri-
tance in Man *606352) cause autosomal recessive motor neuron diseases, including juvenile-onset
amyotrophic lateral sclerosis (JALS),1 juvenile-onset primary lateral sclerosis, and infantile-onset
ascending hereditary spastic paraplegia.2,3 In JALS, both upper and lower motor neurons are affected,
whereas neurodegeneration involves only upper motor neurons in juvenile-onset primary lateral
sclerosis and infantile-onset ascending hereditary spastic paraplegia. Despite these differences in neu-
ropathology, almost all mutations in ALS2 described to date result in a clinical phenotype of infantile
onset of limb and facial muscle weakness, accompanied by bulbar symptoms, which generally
progresses to paraplegia during childhood. Rarely, patients with JALS have been reported with lower
motor neuron involvement.4 ALS2mutations are distributed widely across the entire coding sequence
and mostly result in loss of protein function.4–6
Using exome sequencing and a candidate gene sequencing approach, we identified mutations in
ALS2 in 2 consanguineous families with a novel phenotype of generalized dystonia and a spastic
quadriparesis.
METHODS Standard protocol approvals, registrations, and patient consents. Study approval was given by each local ethics
committee, and both families gave informed consent.
Subjects. Pedigrees for the families are presented in the figure. The clinical characteristics of the patients are described in the results section.
Genetic methodology. Family 1. Homozygosity mapping (in II:1–II:3) and exome sequencing (in II:2) was performed (figure,
A). Only variants within regions of homozygosity, shared only by the affected siblings, were used for filtering. We filtered out
synonymous variants and any variant present in a range of publicly available databases of sequence variation (dbSNP, 1000
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Genomes, Complete Genomic 69 Database, and National
Heart, Lung, and Blood Institute [NHLBI] Exome Sequencing
Project database).
Family 2. A candidate gene sequencing approach was used in
this family for the following genes: SPG11, Spastizin, and ALS2
(figure, B). All coding exons and flanking intronic sequences were
amplified by touchdown PCR and Sanger sequenced.
RESULTS Clinical features. Family 1.The index case (fig-
ure, A [II:2]) is of Bangladeshi descent. Early motor
milestones were normal; however, she failed to walk
independently, prompting assessment at age 2 years.
Assessment at this time revealed a mild spastic diplegia
with global developmental delay and microcephaly
(below 2nd percentile). She presented to our center at
age 13 years; her examination revealed a few beats of
nystagmus, a facetious smile, and anarthria. There was
marked spasticity and contractures in the limbs with
dystonic posturing of the hands. Global muscle weak-
ness was present with distal lower limb wasting suggest-
ing lower motor neuron involvement. She required a
motorized wheelchair. Subsequently, surgical interven-
tion was required for a rapidly progressive scoliosis. A
trial of L-dopa was not helpful.
Individual II:3 achieved normal motor milestones
up until 12 months of age when he started toe-
walking. Examination at age 7 years revealed micro-
cephaly (2nd to 9th percentile), nystagmoid jerks,
and intermittent head titubation. In the upper and
lower limbs, there was spasticity with clonus and dys-
tonic posturing of the arms and trunk. Gait examina-
tion showed truncal sway, suggestive of ataxia. Neck
flexors were weak as were proximal and distal muscle
groups. Reflexes were pathologically brisk with bilateral
extensor plantars. There was a mild scoliosis.
Brain MRI in patient II:2 showed mild lack of
white matter bulk and some immaturity of the white
matter signal. CSF and an extensive metabolic screen
were normal. A muscle biopsy showed angular
atrophic fibers with grouping of fast and slow fibers
in keeping with a neurogenic component.
Family 2. The index case (figure, B [IV:1]), a 32-year-
old man of Turkish descent (with a similarly affected
sister, IV:2), has a complicated dystonia syndrome. Birth
and earlymilestones were normal: he crawled at the age of
8 months and sat at the age of 9 months. Symptom onset
was at approximately age 2 to 3 years when he developed
an increased tone and difficulty walking. He required a
wheelchair from age 8. Speech impairment was observed
at age 4 years, which progressed to anarthria at age 15.
When he first presented to our hospital at age 18 years, he
had a combination of profound weakness, spasticity, and
generalized dystonia with dystonic grimacing, intermit-
tent retrocollis, and severe opisthotonus. He is of small
stature. Neuraxis MRI, electrophysiology (nerve conduc-
tion studies, somatosensory evoked potentials, and blink
reflex), and neuropsychological testing were normal at age
18. The patient underwent deep brain stimulation sur-
gery at age 25 years with an unsatisfactory response and
further progressive decline. Presently, he is in a cachectic
state and lives in a home. He is anarthric and commu-
nicates with his eyes. Cognitive function appears relatively
intact. Vision is normal. He has dysphagia requiring a
percutaneous endoscopic gastrostomy and is incontinent
of urine. He has profound muscle atrophy with severe
weakness and contractures in both upper and lower
limbs. He is on baclofen, tizanidine, and tetrazepam,
and receives focal botulinum toxin injections.
See videos 1 and 2 on the Neurology® Web site at
Neurology.org, which show affected individuals from
families 1 and 2.
Genetic results. Family 1. After exome variant filtering,
one novel homozygous variant remained, c.G2002T:
p.G668X in ALS2 (ENST00000264276). Sanger
Figure Pedigree for family 1 (A) and family 2 (B)
An arrow indicates the proband in each family.
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sequencing revealed that both affected siblings (II:2 and
II:3) are homozygous for the mutation. Their parents
(I:1 and I:2) are heterozygous carriers and the unaffected
sibling (II:1) does not carry the mutation.
Family 2. Sanger sequencing of SPG11 and Spastizin
did not reveal any pathogenic mutations. A homozy-
gous frameshift mutation, c.4573dupG; p.V1525fs
(ENST00000264276), was identified in the ALS2
gene in both IV:1 and IV:2, but was not present in
the unaffected siblings. The parents were confirmed to
be heterozygous carriers of the mutation. Three stop-
gain, 1 frameshift, and no splicing ALS2 variants are
recorded in the NHLBI Exome Variant Server in
approximately 11,840 alleles. The ALS2 mutations in
family 1 and 2 are absent from this database.
DISCUSSION The differential diagnosis of auto-
somal recessive dystonia-spasticity syndromes is wide.
Tyrosine hydroxylase deficiency may be complicated
by additional signs, such as ptosis or oculogyric crises,
and is important to exclude as a differential because
early treatment with L-dopa can influence outcome.
Patients with parkin mutations can present with foot
dystonia, parkinsonism, and brisk reflexes. FBXO7
mutations are associated with a parkinsonian-pyramidal
phenotype sometimes accompanied by dystonia. Several
of the autosomal recessive spastic paraparesis syndromes
can be complicated by dystonia, among other signs (e.g.,
thinning of the corpus callosum occurs in SPG11 while
retinal degeneration and mental retardation can occur in
SPG15). Finally, several neurometabolic conditions can
present with a young-onset dystonia-spasticity-ataxia
syndrome (e.g., GM1 gangliosidosis, Kufs disease type
B, and Niemann-Pick disease type C). The prioritization
of genetic testing in patients is guided by the presence or
absence of additional signs.
We report generalized dystonia, poorly responsive to
deep brain stimulation, in association with ALS2-related
disease. Other novel clinical findings in family 1 include
microcephaly and cerebellar signs. It is not clear whether
microcephaly or cerebellar signs are a result of the ALS2
mutation. Additional detailed clinical descriptions of
patients with ALS2 mutations will help to clarify this.
In a wild-type mice model of the disease, ALS2 was
highly expressed in the granular and Purkinje layers of
the cerebellum, and ALS2-null mice have been found to
develop an age-dependent slowly progressive loss of cere-
bellar Purkinje cells.7 The ALS2 protein binds to a small
guanosine triphosphatase RAB5 and functions as a gua-
nine nucleotide exchange factor for RAB5 and has a role
in intracellular endosomal trafficking,7 highlighting that
this may be an important biological pathway or mech-
anism through which dystonia may occur.
This report adds to the growing literature widen-
ing the phenotypic spectrum of genetic disorders
using next-generation sequencing. We propose that
the ALS2 gene should be screened for mutations in
patients who present with a similar phenotype.
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